Effect of zoledronic acid compared with raloxifene on bone turnover markers in postmenopausal women with low bone density

Menopause

Volumn 18, Issue 8, 2011, Pages 851-856

  Bachmann, Gloria ^a   Kriegman, Audrey ^b   Gonçalves, Joana ^b   Kianifard, Farid ^b   Warren, Michelle ^c   Simon, James A ^d  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c Columbia University College of Physicians and Surgeons ^*  (United States)

^d GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

Bone turnover markers; Low bone mineral density; Osteopenia; Osteoporosis; Raloxifene; Zoledronic acid

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; BIOLOGICAL MARKER; RALOXIFENE; ZOLEDRONIC ACID;

ADULT; AGED; ARTHRALGIA; ARTICLE; BACKACHE; BONE DENSITY; BONE TURNOVER; CHILL; CONSTIPATION; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FEVER; FLU LIKE SYNDROME; HERPES ZOSTER; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MYALGIA; NAUSEA; OSSIFICATION; OSTEOLYSIS; PAIN; PATIENT COMPLIANCE; PEPTIC ULCER BLEEDING; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINUSITIS; SYMPTOM; URINARY TRACT INFECTION; VITAL SIGN;

AGED; BIOLOGICAL MARKERS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; COLLAGEN TYPE I; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMIDAZOLES; INFUSIONS, INTRAVENOUS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PEPTIDES; SELECTIVE ESTROGEN RECEPTOR MODULATORS; UNITED STATES;

EID: 80051550667     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/gme.0b013e31820b80f1     Document Type: Article

References (23)

1. Looker AC, Melton LJ, Harris TB, Borrud LG, Shepherd JA. Prevalence and trends in low femur bone density among older US adults: NHANES 2005-2006 compared with NHANES III. J Bone Miner Res 2009;25: 64-71.
2. Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res 2007;22:465-475. (Pubitemid 46797130)
3. Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 2006;17: 1726-1733. (Pubitemid 44607392)
4. Hallberg I, Rosenqvist AM, Kartous L, Löfman O, Wahlström O, Toss G. Health-related quality of life after osteoporotic fractures. Osteoporos Int 2004;15:834-841. (Pubitemid 39361955)
5. Department of Health and Human Services. The frequency of bone disease. In: Bone Health and Osteoporosis: A Report of the Surgeon General. Rockville, MD: DHHS, Office of the Surgeon General, 2004. Available at: http://www.surgeongeneral.gov/library/bonehealth/chapter-4.html# Prevalence. Accessed August 5, 2009.
6. Black DM, Delmas PD, Eastell R, et al; HORIZON Pivotal Fracture Trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809-1822. (Pubitemid 46698462)
7. McClung M, Miller P, Recknor C, Mesenbrink P, Bucci-Rechtweg C, Benhamou C-L. Zoledronic acid for the prevention of bone loss in postmenopausal women with low bone mass. Obstet Gynecol 2009;114: 999-1007.
8. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999;282: 637-645. (Pubitemid 29384151)
9. Evista [package insert]. Indianapolis, IN: Eli Lilly and Company, 2008.
10. Garnero P. Biomarkers for osteoporosis management: utility in diagnosis, fracture risk prediction and therapy monitoring. Mol Diagn Ther 2008;12:157-170. (Pubitemid 351754589)
11. Garnero P, Sornay-Rendu E, Claustrat B, Delmas PD. Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J Bone Miner Res 2000; 15:1526-1536. (Pubitemid 30484522)
12. Eastell R, Barton I, Hannon RA, Chines A, Garnero P, Delmas PD. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 2003;18:1051-1056. (Pubitemid 37294942)
13. Johnell O, Scheele WH, Lu Y, Reginster JY, Need AG, Seeman E. Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2002;87:985-992. (Pubitemid 36121052)
14. Sambrook PN, Geusens P, Ribot C, et al. Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (Efficacy of FOSAMAXA versus EVISTAA Comparison Trial) International. J Intern Med 2004;255:503-511. (Pubitemid 38446364)
15. Luckey M, Kagan R, Greenspan S, et al. Once-weekly alendronate 70 mg and raloxifene 60 mg daily in the treatment of postmenopausal osteoporosis. Menopause 2004;11:405-415. (Pubitemid 40362164)
16. Recker RR, Kendler D, Recknor CP, et al. Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass. Bone 2007;40:843-851. (Pubitemid 46386535)
17. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001;285:785-795.
18. Brown JP. Results and Implications of the FACT Trial: A Canadian Thought Leader Perspective From Jacques P. Brown, MD. 2004. Available at: http://www.medscape.com/viewarticle/491653. Accessed April 1, 2009.
19. Briesacher BA, Andrade SE, Yood RA, Kahler KH. Consequences of poor compliance with bisphosphonates. Bone 2007;41:882-887. (Pubitemid 47593009)
20. Caro JJ, Ishak KJ, Huybrechts KF, Raggio G, Naujoks C. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 2004;15:1003-1008. (Pubitemid 40064656)
21. Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 2006;81:1013-1022. (Pubitemid 44175011)
22. Rabenda V, Mertens R, Fabri V, et al. Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos Int 2008;19:811-818.
23. Weycker D, Macarios D, Edlesberg J, Oster G. Compliance with osteoporosis drug therapy and risk of fracture. Osteoporos Int 2007;18: 271-277. (Pubitemid 46233172)